{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:56:37Z","timestamp":1790146597553,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2011-3","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T09:02:54Z","timestamp":1566205374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-7177","authenticated-orcid":false,"given":"Boris R.","family":"Minev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette M.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Minev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio F.","family":"Santidrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobrin","family":"Draganov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet O.","family":"Killinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vyalkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"McClay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Carabulea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladar A.","family":"Szalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"2011_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2011_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325.","journal-title":"Cancer Cell"},{"issue":"10135","key":"2011_CR3","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pages","year":"2018","unstructured":"Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128\u201339.","journal-title":"Lancet"},{"issue":"11","key":"2011_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41416-018-0309-1","volume":"119","author":"F Bertucci","year":"2018","unstructured":"Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer. 2018;119(11):1383\u201391.","journal-title":"Br J Cancer"},{"issue":"2","key":"2011_CR5","doi-asserted-by":"publisher","first-page":"e1253654","DOI":"10.1080\/2162402X.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6(2):e1253654.","journal-title":"Oncoimmunology"},{"issue":"8","key":"2011_CR6","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930\u201340.","journal-title":"J Clin Investig"},{"issue":"suppl_12","key":"2011_CR7","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28(suppl_12):xii33\u201343.","journal-title":"Ann Oncol"},{"key":"2011_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41417-018-0042-1","volume":"26","author":"A Dyer","year":"2018","unstructured":"Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 2018;26:59\u201373.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"2011_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","volume":"170","author":"J Haanen","year":"2017","unstructured":"Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055\u20136.","journal-title":"Cell"},{"key":"2011_CR10","doi-asserted-by":"publisher","first-page":"jlb.5RU0117-040","DOI":"10.1189\/jlb.5RU0117-040R","volume":"102","author":"J De Munck","year":"2017","unstructured":"De Munck J, Binks A, McNeish IA, Aerts JL. Oncolytic virus-induced cell death and immunity: a match made in heaven? J Leukoc Biol. 2017;102:jlb.5RU0117-040R.","journal-title":"J Leukoc Biol"},{"issue":"6","key":"2011_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/fvl.10.58","volume":"5","author":"NG Chen","year":"2010","unstructured":"Chen NG, Szalay AA. Oncolytic vaccinia virus: a theranostic agent for cancer. Future Virol. 2010;5(6):763\u201384.","journal-title":"Future Virol"},{"key":"2011_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1586\/erv.11.79","volume":"10","author":"SR Walsh","year":"2011","unstructured":"Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011;10:1221\u201340.","journal-title":"Expert Rev Vaccines"},{"key":"2011_CR13","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","volume":"23","author":"LK Mell","year":"2017","unstructured":"Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, et al. Phase I trial of intravenous oncolytic vaccinia virus (Gl-Onc1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res. 2017;23:5696\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2011_CR14","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","volume":"24","author":"UM Lauer","year":"2018","unstructured":"Lauer UM, Schell M, Beil J, Berchtold S, Koppenhofer U, Glatzle J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. Clin Cancer Res. 2018;24(18):4388\u201398.","journal-title":"Clin Cancer Res"},{"key":"2011_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/DDDT.S3687","volume":"4","author":"A Nalca","year":"2010","unstructured":"Nalca A, Zumbrun EE. ACAM2000\u2122: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010;4:71\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"2011_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2004.09.002","volume":"8","author":"TP Monath","year":"2004","unstructured":"Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014a second-generation smallpox vaccine for biological defense. Int J Infect Dis. 2004;8:31\u201344.","journal-title":"Int J Infect Dis"},{"key":"2011_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nm916","volume":"9","author":"R Weltzin","year":"2003","unstructured":"Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003;9:1125\u201330.","journal-title":"Nat Med"},{"key":"2011_CR18","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1016\/j.vaccine.2007.10.040","volume":"25","author":"JD Osborne","year":"2007","unstructured":"Osborne JD, Da Silva M, Frace AM, Sammons SA, Olsen-Rasmussen M, Upton C, et al. Genomic differences of vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine. 2007;25:8807\u201332.","journal-title":"Vaccine"},{"issue":"8","key":"2011_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/mt.2016.101","volume":"24","author":"S Downs-Canner","year":"2016","unstructured":"Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O\u2019Malley ME, Jones HL, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther. 2016;24(8):1492\u2013501.","journal-title":"Mol Ther"},{"key":"2011_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.critrevonc.2015.04.001","volume":"95","author":"A Jefferson","year":"2015","unstructured":"Jefferson A, Cadet VE, Hielscher A. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. Crit Rev Oncol Hematol. 2015;95:407\u201316.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6040","key":"2011_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/317813a0","volume":"317","author":"RM Buller","year":"1985","unstructured":"Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317(6040):813\u20135.","journal-title":"Nature"},{"issue":"22","key":"2011_CR22","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.1073\/pnas.0901329106","volume":"106","author":"RJ Critchley-Thorne","year":"2009","unstructured":"Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA. 2009;106(22):9010\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2011_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/mt.2015.49","volume":"23","author":"L Evgin","year":"2015","unstructured":"Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, et al. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015;23:1066\u201376.","journal-title":"Mol Ther"},{"issue":"2","key":"2011_CR24","first-page":"290","volume":"1866","author":"G Lazennec","year":"2016","unstructured":"Lazennec G, Lam PY. Recent discoveries concerning the tumor\u2014mesenchymal stem cell interactions. Biochim Biophys Acta. 2016;1866(2):290\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"2011_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/0748806817691152","volume":"3","author":"M Berman","year":"2017","unstructured":"Berman M, Lander E. A prospective safety study of autologous adipose-derived stromal vascular fraction using a specialized surgical processing system. Am J Cosmetic Surg. 2017;3:129\u201342.","journal-title":"Am J Cosmetic Surg"},{"issue":"1\u20132","key":"2011_CR26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jviromet.2008.05.028","volume":"152","author":"Trindade G de Souza","year":"2008","unstructured":"de Souza Trindade G, Li Y, Olson VA, Emerson G, Regnery RL, da Fonseca FG, et al. Real-time PCR assay to identify variants of Vaccinia virus: implications for the diagnosis of bovine vaccinia in Brazil. J Virol Methods. 2008;152(1\u20132):63\u201371.","journal-title":"J Virol Methods"},{"issue":"24","key":"2011_CR27","first-page":"8751","volume":"61","author":"JA McCart","year":"2001","unstructured":"McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Can Res. 2001;61(24):8751\u20137.","journal-title":"Can Res"},{"issue":"6","key":"2011_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533\u201342.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2011_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1086\/422999","volume":"39","author":"RJ Hopkins","year":"2004","unstructured":"Hopkins RJ, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis. 2004;39(6):819\u201326.","journal-title":"Clin Infect Dis"},{"key":"2011_CR30","doi-asserted-by":"publisher","first-page":"P112","DOI":"10.1186\/2051-1426-2-S3-P112","volume":"2","author":"B Minev","year":"2014","unstructured":"Minev B, Kohrt H, Kilinc M, Chen N, Feng A, Pessian M, et al. Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation. J Immunother Cancer. 2014;2:P112.","journal-title":"J Immunother Cancer"},{"issue":"226","key":"2011_CR31","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2011_CR32","doi-asserted-by":"publisher","first-page":"1109\u20131119.e10","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u20131119.e10.","journal-title":"Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2011-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T23:13:18Z","timestamp":1597705998000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2011-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2011-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the International Cell Surgical Society Institutional Review Board. Written informed consent was obtained from all patients prior to treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The images for patient #21 and patient #47 included in this manuscript are entirely unidentifiable and there are no patient identification details on individuals reported within the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BM, IM, AS, DN, DD, MK, and AAS are employees and\/or shareholders in Calidi Biotherapeutics. No non-financial conflicts of interest exist for any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}